Clinical Trial Update: Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization [Phase 3]

View source ↗

Summary

A Phase 3 Pfizer-sponsored trial evaluating the impact of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal colonization has completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Infections | Phase 3 | Status: COMPLETED | Results posted: 2012-07-13